OCUMENSION-B (01477.HK): Phase III Trial of Dry Eye Drug OT-211 Completes Enrollment of 398 Patients in China

NewTimeSpace News: On 2 September 2026, Ocumension Therapeutics (stock code: 01477.HK) announced, on a voluntary basis, that its Phase III clinical trial of OT-211 (TRYPTYR, acoltremon ophthalmic solution) conducted in the PRC has recently completed enrollment of an aggregate of 398 patients.
OT-211 is a 0.003% ophthalmic solution and the first TRPM8 agonist approved by the US FDA for the treatment of dry eye disease (DED). In March 2026, the Phase III trial of OT-211 in China completed enrollment of its first patient, marking an important milestone in its clinical development in the country.
Alcon Inc., a global leader in eye care whose business spans the two complementary segments of surgical and vision care, developed the 0.003% formulation of AR-15512 and completed one Phase IIb and three Phase III clinical trials. OT-211 received FDA approval on 28 May 2025 for the treatment of the signs and symptoms of DED.
Following a strategic collaboration with the Alcon Group in October 2024, the Group obtained an exclusive license to develop, manufacture, contract manufacture, import, export and sell OT-211 in the Chinese mainland. The successful enrollment marks a strong partnership and alignment between the Company and the Alcon Group in new drug development, laying the groundwork for future joint exploration and development of new drugs.

View announcement.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.